Profile data is unavailable for this security.
About the company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
- Revenue in USD (TTM)0.00
- Net income in USD-17.05m
- Incorporated2009
- Employees15.00
- LocationGenprex Inc3300 Bee Cave Road, Suite 650-227AUSTIN 78746United StatesUSA
- Phone+1 (512) 537-7997
- Fax+1 (302) 655-5049
- Websitehttps://www.genprex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.26m | 8.00 | -- | 0.3339 | -- | 8.73 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 148.34k | -555.16k | 4.65m | 2.00 | -- | -- | -- | 31.35 | -0.00006 | -0.00006 | 0.00001 | -0.0001 | 4.55 | -- | 11.35 | 74,170.00 | -1,702.42 | -652.66 | -- | -- | 73.11 | 87.76 | -374.25 | -177.59 | -- | -4.30 | -- | -- | 21.77 | 0.8662 | 15.74 | -- | -- | -- |
| Genprex Inc | 0.00 | -17.05m | 4.68m | 15.00 | -- | 2.64 | -- | -- | -52.85 | -52.85 | 0.00 | 0.7646 | 0.00 | -- | -- | 0.00 | -448.99 | -100.44 | -1,253.41 | -109.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.69 | -- | -- | -- |
| Decoy Therapeutics Inc | 0.00 | -5.00m | 4.72m | 2.00 | -- | 0.1643 | -- | -- | -39.19 | -39.19 | 0.00 | 4.50 | 0.00 | -- | -- | 0.00 | -100.54 | -73.17 | -139.55 | -84.56 | -- | -- | -- | -987.44 | -- | -- | 0.00 | -- | -- | -- | 55.55 | -- | -- | -- |
| Bio Green Med Solution Inc | 81.00k | -6.97m | 4.81m | 12.00 | -- | 0.4835 | -- | 59.32 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| Bioxytran Inc | 0.00 | -2.11m | 4.81m | 2.00 | -- | -- | -- | -- | -0.0235 | -0.0235 | 0.00 | -0.0326 | 0.00 | -- | -- | -- | -1,340.44 | -1,468.56 | -- | -- | -- | -- | -- | -- | -- | -1.99 | -- | -- | -- | -- | 47.08 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 4.91m | 1.00 | -- | 0.4843 | -- | 1.72 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 4.95m | -- | -- | -- | -- | 2,551.26 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
| Weed Inc | 0.00 | -755.25k | 4.96m | 2.00 | -- | -- | -- | -- | -0.0058 | -0.0058 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -133.78 | -117.17 | -- | -371.94 | -- | -- | -- | -- | -- | -22.55 | -- | -- | -- | -- | -1,518.25 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 4.97m | 11.00 | -- | 0.7125 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 4.98m | 2.00 | -- | 0.8478 | -- | 1.74 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -9.17m | 5.02m | 4.00 | -- | 0.9751 | -- | -- | -8.54 | -8.54 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -151.72 | -158.12 | -291.07 | -208.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.26 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -12.93m | 5.03m | 10.00 | -- | 0.8047 | -- | -- | -35.00 | -35.00 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -206.50 | -104.23 | -270.68 | -112.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.47m | -2.30m | 5.06m | 30.00 | -- | 0.5641 | -- | 0.5345 | -1.28 | -1.28 | 5.27 | 3.79 | 1.02 | 6.73 | 6.42 | -- | -24.68 | -6.00 | -27.80 | -7.75 | 14.77 | 14.31 | -24.27 | -4.98 | 6.81 | -1,354.05 | 0.00 | -- | -2.66 | 137.09 | 39.20 | -- | 77.67 | -- |
| VivoSim Labs Inc | 140.00k | -1.98m | 5.22m | 5.00 | -- | 0.7383 | -- | 37.26 | -0.1898 | -0.1898 | 0.068 | 2.71 | 0.017 | -- | 4.59 | 10,769.23 | -24.12 | -51.63 | -34.26 | -56.47 | 98.57 | -- | -1,416.43 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 5.25m | 9.00 | -- | 2.47 | -- | 45.01 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Genprex Inc's reporting currency: US Dollar USD
1.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 11.70k | 0.51% |
| G1 Execution Services LLCas of 30 Sep 2025 | 6.80k | 0.29% |
| Schiketanz Capital Advisors GmbHas of 29 Aug 2025 | 2.31k | 0.10% |
| Miller Wealth Advisors LLCas of 31 Dec 2025 | 1.20k | 0.05% |
| Cheviot Value Management LLCas of 31 Dec 2025 | 1.00k | 0.04% |
| HUB Investment Partners LLCas of 30 Sep 2025 | 340.00 | 0.02% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 188.00 | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 152.00 | 0.01% |
| Tower Research Capital LLCas of 30 Sep 2025 | 116.00 | 0.01% |
| UBS Securities LLCas of 31 Dec 2025 | 88.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
